GET DAILY SIGNALSWhy Is Agenus Inc. (AGEN) Stock Down -2.44% Today?
Key Takeaways
- AGEN shares slipped about 2.44% to $6.80 in intraday trading, pulling back from the prior session's close of $6.97.
- The decline came despite a profitable third-quarter report, pointing to a classic "sell the news" reaction after a roughly 4.5% run-up the prior day.
- Agenus posted its third consecutive quarter of positive operating income and announced its first worldwide marketing authorizations for its BOT+BAL combination in Armenia.
- Investors appeared to focus on caveats: the Armenian approvals are conditional, BOT+BAL is not FDA-approved, and a large share of revenue is non-cash.
- Biotechnology sector sentiment and profit-taking in a volatile small-cap name compounded the intraday pressure.
- Traders are now watching the company's November 2026 SITC data presentations and the Phase 3 ROBBIN trial timeline.
- For additional detail on Price Targets, Earnings, and Forecast for AGEN, explore the dedicated analysis pages.
- To see how AI-driven strategies are positioning across thousands of tickers, explore Trending AI Robots.
Opening Summary
Agenus Inc. (AGEN), a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts, saw its shares decline about 2.44% in Thursday's session, trading near $6.80 versus a prior close of $6.97. The move lower followed the company's pre-market release of third-quarter 2026 results, which were broadly positive on headline metrics but failed to sustain the stock's prior-day momentum. The pullback reflects profit-taking and a "sell the news" dynamic in a high-beta small-cap biotech, even as the underlying fundamentals showed continued operational improvement.
Earnings Results: A Profitable Quarter Met by Selling
Agenus reported total revenue of $31.5 million for the third quarter of 2026, up from $30.2 million a year earlier, and delivered operating income of $11.4 million — its third consecutive quarter of positive operating income, compared with an operating loss of $4.6 million in the year-ago period. Net income came in at $2.8 million, contributing to $41.4 million of net income for the first nine months of the year.
Despite the profitability milestone, investors appeared to weigh the composition of the revenue more carefully. Of the quarterly total, $25.5 million consisted of non-cash royalty revenue tied to royalty interests Agenus previously monetized — money that does not generate cash for the company. Pre-commercial product sales of botensilimab (BOT) and balstilimab (BAL) contributed $6.0 million, down slightly from $6.4 million in the second quarter. This revenue mix gave the market a reason to look past the headline beat and lock in gains.
Regulatory Progress and the "Sell the News" Dynamic
The company also announced that Armenia's Ministry of Health granted marketing authorizations for Botvymo (botensilimab) and Evamplix (balstilimab) for patients with microsatellite-stable metastatic colorectal cancer without active liver metastases who have received prior standard therapies. These represent the first marketing authorizations for either medicine anywhere in the world.
However, the authorizations are conditional and valid for one year, subject to annual renewal, and BOT+BAL remains investigational and is not approved by the U.S. Food and Drug Administration. The gap between international conditional approval and a U.S. regulatory pathway left some investors inclined to take profits, particularly after the stock had already advanced more than 4.5% in the preceding session in anticipation of the results.
Market Context and Trading Activity
The decline unfolded amid a broader pattern of volatility that has characterized small-cap biotechnology names. AGEN shares have swung sharply in recent weeks, and the stock remains well above its 52-week low near $2.71 but below its 52-week high near $10.31. The intraday pullback reflected consolidation following a catalyst-driven rally rather than a broad deterioration in the company's clinical or financial position.
Trading activity was consistent with a stock digesting news, as investors reassessed the near-term catalysts. With the Phase 3 ROBBIN trial — a global randomized study in high-risk Stage II or Stage III MSS/pMMR colon cancer — not expected to begin enrolling patients until the first quarter of 2027, the market may have judged that the next major value inflection point is further out on the horizon.
What Comes Next for AGEN
Looking ahead, several catalysts could shape the trajectory of AGEN. The company plans to present long-term survivor characteristics and translational research data for BOT+BAL at the SITC 2026 conference in November. Initiation and first patient enrollment for the ROBBIN Phase 3 trial are targeted for the first quarter of 2027, with a milestone-aligned warrant structure that could provide up to roughly $255 million in additional gross proceeds if fully exercised.
Investors will also be monitoring whether Agenus can convert its Armenia approvals into additional marketing authorizations within the Eurasian Economic Union and build on its strengthened cash position, which stood at $86.9 million at quarter-end. Key risks include the conditional nature of current approvals, the absence of U.S. regulatory clearance, and the inherent uncertainty of late-stage clinical development in immuno-oncology.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are highlighted in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to see which automated approaches are currently leading the market. Explore the Trending AI Robots page to discover the strategies gaining traction today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AGEN in -7.90% downward trend, falling for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AGEN declined for three days, in 284 of 316 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 49 cases where AGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
AGEN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AGEN crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AGEN's RSI Indicator exited the oversold zone, 33 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AGEN as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for AGEN just turned positive on October 29, 2026. Looking at past instances where AGEN's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGEN advanced for three days, in 219 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 65 of 94 cases where AGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. AGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.581) is normal, around the industry mean (2.904). P/E Ratio (2.323) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (1.994) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is an Inverted Yield Curve?
What Is a Dotcom?
6 Benefits of Finding Stock Chart Patterns in Real Time
Cyclacel Pharmaceuticals ( CYCC ) Stock Soars 251.95% in Five Days: Catalysts, Correlations, and AI-Driven Trading Opportunities
AI Trading Robots with the Best Narratives: 2026 Predictions for Retail Traders
General Information
a developer of technologies to treat cancers and infectious diseases
Industry Biotechnology
Advertisement